AGENNIX AG i.L.

EANS-News: AGENNIX AG /

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 

6-month report

Heidelberg (euro adhoc) - Agennix AG Schedules Conference Call on August 5, 2010 to Discuss First Half of 2010 Financial Results

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 29, 2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will hold a conference call to discuss financial results for the second quarter and first half of 2010 and to provide a business update. The results will be published on Thursday, August 5, 2010 in advance of the conference call.

The conference call, which will be conducted in English, will be held on Thursday, August 5, 2010 at 9 AM ET/3 PM CET.

A live webcast will be available on the Agennix Web site at www.agennix.com. A replay will be available via the Web site following the live event.

Dial-in numbers for the call are as follows:

Participants from Europe:       0049 (0)69 71044 5598
                                0044 (0)20 3003 2666
Participants from the U.S.:     1-646-843-4608 

Please dial in 10 minutes before the beginning of the meeting.

About Agennix Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies to improve the length and quality of life of seriously ill patients in areas of major unmet medical need. The Company´s most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

For further information, please contact:

Agennix AG Investor Relations & Corporate Communications Phone: +49 (0)89 8565 2693 ir@agennix.com

In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884
laurie.doyle@agennix.com 

Additional media contacts for Europe: MC Services AG Phone: +49 (0) 89 210 228 0

Raimund Gabriel raimund.gabriel@mc-services.eu

Hilda Juhasz

hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com 
end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:

For further information, please contact:


Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com


Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu

Hilda Juhasz
hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade
Original-Content von: AGENNIX AG i.L., übermittelt durch news aktuell

Das könnte Sie auch interessieren: